The phase II trial data of moderate to severe allergic dermatitis drug ANB020 is encouraging
October 13, 2017 Source: Yaodu
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];ANAB (AnaptysBio, Inc) is a biotechnology company focused on clinical research. Today, ANAB announced that it has received positive proof-of-concept data in a clinical phase II trial of the drug ANB020 for the treatment of moderate to severe allergic dermatitis.
A total of 12 adults with moderate to severe allergic dermatitis were enrolled in the clinical trial. Initially, these patients received a 2-week placebo treatment followed by an intravenous dose of 300 mg of ANB020 for 1 week followed by placebo. The clinical response of the drug was judged by the EASI (Eczema Area Severity Index), a measure of the severity of atopic dermatitis. The patient's itching Chengdu was judged by a 5-D itching score table. After 5 days of treatment with ANB020, markers of response to disease progression were explored by detecting localized skin granulocyte infiltration and cytokine levels.
After receiving a single dose of ANB020 for 15 days, 75% of patients had an EASI score of 50% (EASI-50); after 29 days of treatment, 83% achieved EASI-50; after 57 days of treatment, 75% achieved EASI -50. All 12 patients achieved EASI-50 at one or more time points and all patients showed good tolerance to ANB020.
Graham Ogg, a professor of dermatology at Oxford University and a phase II trial at ANB020, said: "Medium and severe allergic dermatitis is a serious disease associated with chronic skin inflammation and debilitating itching. The treatment of this disease has not yet met medical treatment. Demand. After a single dose of ANB020 treatment, the patient has a rapid and sustained effect. The trial is encouraging in Russia. We look forward to further research on ANB020, and ultimately provide treatment options for patients with moderate to severe allergic dermatitis. â€
Product category of Fresh Ginger;We are a professional manufacturer from China, fresh ginger, air-dried ginger supplier/factory, wholesale high-quality fresh ginger research and development and manufacturing products, our company mainly processing and exporting ginger, perennial processing and sales export air-dried ginger, fresh ginger, specification: 50g, 150g, 250g, 300g, 350g.There are calcium plastic boxes, boxes and mesh bags. Our company has its own factory below. There is an assembly line of ginger washing equipment.We have perfect after - sales service and technical support.Looking forward to your cooperation!
Tender Ginger,Fresh Tender Ginger,New Crop Ginger,Organic Fresh Ginger
Jining Sunagro Trade Co., Ltd. , https://www.sunagro-food.com